Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
5.21
Aug 21 • 3:59 PM ET Dollar change+0.44 Percentage change(9.22%)
Aftermarket Close
5.28
Aftermarket • 5:58 PM ET Dollar change+0.07 Percentage change(1.40%)
Today, 7:35 AMArbutus Biopharma to launch modified Dutch auction tender offer to repurchase up to US$230M of common shares at US$5.00–US$5.75
Index
RUT
Market Cap
1.03B
Enterprise Value
941.78M
Income
153.05M
Sales
181.72M
Book/sh
1.31
Cash/sh
0.47
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
19
IPO
Jul 23, 2007
P/E
6.65
Forward P/E
-
PEG
-
P/S
5.67
P/B
3.98
P/C
11.13
P/FCF
-
EV/EBITDA
6.39
EV/Sales
5.18
Quick Ratio
81.42
Current Ratio
81.42
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
0.78
EPS next Y
-0.08
EPS next Q
-0.02
EPS this Y
535.29%
EPS next Y
-110.81%
EPS next 5Y
-
EPS past 3/5Y
27.58% 29.45%
Sales past 3/5Y
-28.80% 15.29%
EPS Y/Y TTM
376.44%
Sales Y/Y TTM
1078.78%
EPS Q/Q
-298.47%
Sales Q/Q
-90.56%
Insider Own
20.46%
Insider Trans
0.00%
Inst Own
71.48%
Inst Trans
2.35%
ROA
81.13%
ROE
89.58%
ROIC
58.45%
Gross Margin
99.98%
Oper. Margin
81.13%
Profit Margin
84.23%
SMA20
13.21%
SMA50
13.10%
SMA200
16.75%
Trades
Shs Outstand
197.63M
Shs Float
157.37M
52W High
5.38 -3.16%
52W Low
3.44 51.45%
Volatility
4.67% 3.83%
ATR (14)
0.23
RSI (14)
66.89
Beta
0.61
Rel Volume
8.98
Avg Volume
2.01M
Volume
18,059,809
Perf Week
11.56%
Perf Month
16.55%
Perf Quarter
17.34%
Perf Half Y
22.01%
Perf YTD
8.32%
Perf Year
45.53%
Perf 3Y
154.15%
Perf 5Y
78.42%
Perf 10Y
39.30%
Prev Close
4.77
Price
5.21
Change %
9.22%
Date Action Analyst Rating Change Price Target Change
Feb-02-22Upgrade Jefferies Hold → Buy $5
Feb-25-21Initiated Jefferies Hold $5
Dec-17-20Initiated H.C. Wainwright Buy $10
Jul-27-20Resumed JMP Securities Mkt Outperform $10 → $8
Jul-24-20Downgrade Robert W. Baird Outperform → Neutral
May-19-20Upgrade Wedbush Neutral → Outperform
Mar-06-20Upgrade Chardan Capital Markets Neutral → Buy $5
Feb-20-20Initiated Robert W. Baird Outperform $8
Feb-05-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $10
Oct-07-19Reiterated B. Riley FBR Buy $7 → $3
Today 09:32AM
08:56AM
07:30AM
Aug-12-26 07:37AM
07:30AM
06:07AM Loading…
Jul-17-26 06:07AM
Jul-16-26 02:41PM
07:30AM
Jul-07-26 02:28PM
May-13-26 07:36AM
07:30AM
May-01-26 09:05AM
08:27AM
Apr-15-26 07:30AM
Mar-23-26 07:39AM
07:30AM Loading…
07:30AM
Mar-04-26 04:50PM
04:32PM
04:02PM
02:35PM
10:18AM
09:55AM
09:15AM
09:01AM
08:52AM
08:40AM
08:14AM
08:14AM
05:25AM
Mar-03-26 06:58PM
04:15PM Loading…
04:15PM
Feb-18-26 05:18PM
Feb-06-26 12:33PM
Jan-12-26 12:00PM
Nov-13-25 07:30AM
Oct-07-25 08:00AM
Oct-03-25 09:40AM
Sep-17-25 09:40AM
Sep-01-25 09:40AM
Aug-14-25 09:40AM
Aug-06-25 08:40AM
07:45AM
07:30AM
Jun-25-25 07:30AM
May-14-25 08:45AM
07:39AM
07:30AM
May-13-25 05:15PM
09:40AM
May-07-25 02:01AM
Apr-25-25 09:40AM
Apr-24-25 10:02AM
Apr-23-25 02:01AM
Mar-31-25 12:00PM
09:40AM
Mar-28-25 09:48AM
09:00AM
07:01AM
Mar-27-25 08:45AM
07:30AM
Mar-26-25 03:45PM
Mar-03-25 09:15AM
Feb-25-25 07:00AM
Feb-12-25 09:24AM
Jan-16-25 11:22AM
Jan-13-25 07:30AM
Dec-06-24 08:20AM
Dec-03-24 08:00AM
Nov-26-24 07:30AM
Nov-15-24 11:02AM
11:01AM
Nov-14-24 07:30AM
Nov-07-24 02:12AM
02:07AM
Nov-06-24 08:45AM
07:40AM
07:30AM
Oct-23-24 07:30AM
Oct-15-24 08:16AM
Oct-01-24 07:30AM
Sep-25-24 09:40AM
Sep-03-24 07:30AM
Aug-22-24 09:40AM
Aug-06-24 09:40AM
Aug-02-24 01:51AM
Aug-01-24 08:40AM
07:41AM
07:30AM
Jul-18-24 07:30AM
Jun-06-24 11:15AM
11:15AM
Jun-05-24 02:30AM
May-29-24 07:30AM
May-22-24 02:00AM
May-17-24 12:03PM
10:40AM
09:00AM
May-07-24 07:30AM
May-03-24 11:19AM
03:24AM
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
M.B.A.Ms. Lindsay Androski J.D.
Chief Financial OfficerMr. Tuan Nguyen
General CounselMr. Andrew J. Sung
J.D.Mr. R. Hector Mackay-Dunn B.A.